Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial Meeting Abstract
| Authors: | Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Sizer, B.; Goebell, P. J.; De Bono, J. S.; Paliwal, P.; Durham, S.; Cheng, S.; Logothetis, C. |
| Abstract Title: | Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial |
| Meeting Title: | 2013 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2013 Feb 14-16 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-02-20 |
| Language: | English |
| ACCESSION: | WOS:000333679600002 |
| DOI: | 10.1200/jco.2013.31.6_suppl.lba8 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA8 -- Source: Wos |
